Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis

Table 2

Subgroup analyses stratified by TNFi types and assay methods for ADAb detection.

Group or subgroup	3 months			6 months			12 months			≥24 months
		Model	OR (95% CI)		Model	OR (95% CI)		Model	OR (95% CI)		Model	OR (95% CI)
Total	3	F	0.03 (0.01, 0.13)	5	R	0.04 (0.01, 0.22)	6	R	0.26 (0.11, 0.57)	2	F	0.16 (0.08, 0.33)
TNFi
ADAL	2	F	0.02 (0.00, 0.21)	3	R	0.02 (0.00, 0.62)	1	—	0.06 (0.01, 0.34)	1	—	0.18 (0.08, 0.38)
INF	1	—	0.05 (0.01, 0.27)	2	R	0.05 (0.00, 1.06)	4	F	0.49 (0.29, 0.81)	1	—	0.11 (0.02, 0.58)
Combine	NA	NA	NA	NA	NA	NA	1	—	0.18 (0.05, 0.58)	NA	NA	NA
Assay
RIA	2	F	0.03 (0.01, 0.11)	3	R	0.02 (0.00, 0.63)	NA	NA	NA	1	—	0.18 (0.08, 0.38)
ELISA	1	—	0.10 (0.01, 2.41)	2	R	0.05 (0.00, 1.13)	5	F	0.20 (0.10, 0.38)	1	—	0.11 (0.02, 0.58)
IMPACT	NA	NA	NA	NA	NA	NA	1	—	0.66 (0.35, 1.24)	NA	NA	NA

TNFi: tumor necrosis factor inhibitors; ADAL: adalimumab; INF: infliximab; ETN: etanercept; combine: INF/ETN/ADAL; OR: odds ratio; CI: confidence interval; R: randomized-effects model; F: fixed-effects model; —: no model was used; NA: not available; ELISA: enzyme-linked immunosorbent assay; RIA: radioimmunoassay; IMPACT: Immunological Multi-Parameter Chip Technology.